Published in Hepatology on June 01, 1995
Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut (1998) 2.47
Hepatocellular carcinoma. Postgrad Med J (2000) 1.67
Is human hepatocellular carcinoma a hormone-responsive tumor? World J Gastroenterol (2008) 0.99
Management of hepatocellular carcinoma. J Cancer Res Clin Oncol (2014) 0.96
Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. N Am J Med Sci (2011) 0.94
Systemic therapy of hepatocellular carcinoma: current status and future perspectives. World J Gastroenterol (2014) 0.86
Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer (2007) 0.84
Liver expression of steroid hormones and Apolipoprotein D receptors in hepatocellular carcinoma. World J Gastroenterol (2007) 0.83
Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol (2013) 0.81
Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats. World J Gastroenterol (2005) 0.79
Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases. Semin Intervent Radiol (2006) 0.78
Systemic therapy in hepatocellular carcinoma. Clin Liver Dis (2011) 0.78
Update on new approaches in the management of hepatocellular carcinoma. Hepat Med (2010) 0.77
The androgen receptor as an emerging target in hepatocellular carcinoma. J Hepatocell Carcinoma (2015) 0.75
Pituitary protein 7B2 plasma levels in patients with liver disease: Comparisons with other hormones and neuropeptides. Oncol Lett (2013) 0.75
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway? Onco Targets Ther (2017) 0.75
Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med (1981) 3.17
Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus. Hepatology (1983) 2.36
Detection of hepatitis B virus DNA directly in human serum by a simplified molecular hybridization test: comparison to HBeAg/anti-HBe status in HBsAg carriers. Hepatology (1983) 2.10
Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology (1998) 1.67
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol (2001) 1.39
Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology (2001) 1.38
Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat (2008) 1.22
Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther (2001) 1.20
Hepatitis-associated antigen in chronic liver disease. Lancet (1970) 1.19
Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. Eur J Gastroenterol Hepatol (2000) 1.16
Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat (2001) 1.10
Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut (2003) 1.08
Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. J Viral Hepat (2005) 1.06
Liver disease activity and hepatitis B virus replication in chronic delta antigen-positive hepatitis B virus carriers. Hepatology (1985) 1.05
Interrupted replication of hepatitis B virus in liver tissue of HBsAg carriers with hepatocellular carcinoma. Virology (1988) 1.02
Alpha-chain disease with clinical, immunological, and histological recovery. Br Med J (1974) 1.02
Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepat (1998) 1.02
Cholestatic jaundice as a paraneoplastic manifestation of renal cell carcinoma. Eur J Gastroenterol Hepatol (1997) 1.00
Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients. Hepatology (1997) 0.96
Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat (2008) 0.95
Review article: current management of chronic hepatitis B. Aliment Pharmacol Ther (2004) 0.94
Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease. Eur J Gastroenterol Hepatol (1999) 0.91
Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat (2009) 0.91
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J Viral Hepat (2013) 0.90
Gliclazide-induced acute hepatitis. Eur J Gastroenterol Hepatol (2000) 0.89
Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study. Hippokratia (2011) 0.88
Hepatitis C virus infection in Greece and its role in chronic liver disease and hepatocellular carcinoma. J Hepatol (1993) 0.87
Immune thrombocytopenia and alpha-interferon therapy. J Hepatol (1996) 0.86
Hepatocellular carcinoma and type B hepatitis. Clin Gastroenterol (1980) 0.86
Hepatitis G virus infection: clinical characteristics and response to interferon. J Viral Hepat (1997) 0.85
Prolonged cholestatic jaundice after endoscopic retrograde cholangiography. Hepatogastroenterology (1997) 0.85
Chronic hepatitis B. Prog Liver Dis (1990) 0.83
A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther (2006) 0.83
Cellular immune responses in hepatitis B virus e antigen negative chronic hepatitis B. J Viral Hepat (2008) 0.83
Chronic viral hepatitis. Clin Gastroenterol (1974) 0.82
Recombinant interferon-alpha therapy for acute hepatitis B: a randomized, double-blind, placebo-controlled trial. J Viral Hepat (1997) 0.82
Nonparenteral transmission of viral hepatitis in Greece. Am J Med Sci (1977) 0.82
Absence of the negative strand of GBV-C/HGV RNA from the liver. J Hepatol (1999) 0.81
Recurrent hepatic sarcoidosis following liver transplantation. Transplant Proc (1997) 0.81
Does delta infection play a part in the pathogenesis of hepatitis B virus related hepatocellular carcinoma? Br Med J (Clin Res Ed) (1984) 0.80
Group B streptococcus (Streptococcus agalactiae) meningitis in a diabetic adult. Acta Diabetol (2005) 0.80
High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma. J Gen Virol (2011) 0.79
0.48Tb/s (12x40Gb/s) WDM transmission and high-quality thermo-optic switching in dielectric loaded plasmonics. Opt Express (2012) 0.79
Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species. J Hepatol (1997) 0.79
Splenic infarct as a late complication of liver transplantation. Eur J Gastroenterol Hepatol (1998) 0.78
Endemic hepatitis delta virus infection in a Greek community. Prog Clin Biol Res (1987) 0.77
Induction interferon therapy in naïve patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit. Aliment Pharmacol Ther (2001) 0.77
Whole genome analysis of hepatitis B virus from four cases of fulminant hepatitis: genetic variability and its potential role in disease pathogenicity. J Viral Hepat (1996) 0.77
Efficacy of long-term therapy with norfloxacin in chronic bacterial prostatitis. J Chemother (1989) 0.77
Emergence of the long form of hepatitis delta virus antigen in transfected cells after intrahepatic transfection and during natural infection. Prog Clin Biol Res (1993) 0.77
Measurement of hepatitis B viral DNA in serum by solution hybridization and comparison with the dot-blot hybridization technique. Hepatogastroenterology (1991) 0.77
Letter: Hepatitis-B core antigen and antibody in primary liver cancer. Lancet (1975) 0.76
Core variability does not affect response to interferon alpha in HBeAg negative chronic hepatitis B. J Hepatol (1998) 0.76
Molecular pathophysiology of persistent hepatitis B virus infection in relation to chronic liver disease and primary hepatocellular carcinoma. Monogr Pathol (1987) 0.76
Sweat gland carcinoma in a patient with sarcoidosis and primary biliary cirrhosis. Dermatology (1994) 0.75
Autoimmune hepatitis associated with the antiphospholipid syndrome. Eur J Gastroenterol Hepatol (2001) 0.75
Limitations of retrospective IL28B polymorphisms and IP-10 real life studies in hepatitis C. Aliment Pharmacol Ther (2011) 0.75
Decreasing prevalence of hepatitis D virus infection. J Gastroenterol Hepatol (1997) 0.75
Hepatitis B vaccine in haemodialysis patients. Lancet (1984) 0.75
Deep jaundice in an adolescent. Postgrad Med J (2003) 0.75
Acute rhabdomyolysis following quail consumption. Ann Saudi Med (2007) 0.75
Australia antigen in a family. Lancet (1970) 0.75
Proliferative activity in colonic adenomas as a predictor of metachronous adenomas as assessed by proliferating cell nuclear antigen immunohistochemistry. Am J Gastroenterol (1995) 0.75
Fulminant hepatitis after flutamide treatment. J Hepatol (1994) 0.75
Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients. J Hepatol (1990) 0.75
High-gain 1.3 μm GaInNAs semiconductor optical amplifier with enhanced temperature stability for all-optical signal processing at 10 Gb/s. Appl Opt (2015) 0.75
Letter: Detection of HBAg by passive haemagglutination. Lancet (1974) 0.75
Research as a part of education. Scand J Gastroenterol Suppl (1989) 0.75
Modern trends in the management of hepatocellular carcinoma. Drugs Exp Clin Res (1986) 0.75
Use of a monoclonal antibody in the detection of HBsAg in the liver by immunofluorescence. Dev Biol Stand (1983) 0.75
Delta antigen positive chronic liver disease in Greece: clinical aspects and natural course. Prog Clin Biol Res (1983) 0.75
Multi-format all-optical processing based on a large-scale, hybridly integrated photonic circuit. Opt Express (2011) 0.75
The precore sequence of hepatitis B virus is required for nuclear localization of the core protein. Hepatology (1997) 0.75
Primary liver cancer and its relationship to chronic infection with the hepatitis B virus. Springer Semin Immunopathol (1981) 0.75
HBeAg-negative hepatitis B in a previously thalassemic patient during immunosuppressive therapy for chronic GVHD. Bone Marrow Transplant (1998) 0.75
Size of the speciality. Scand J Gastroenterol Suppl (1989) 0.75
Serum HBV-DNA in delta antigen positive chronic liver disease. Dev Biol Stand (1985) 0.75